Shopping Cart 0
Cart Subtotal
AED 0

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 12845

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 25690

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 38535

Details

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)-Pipeline Review, H2 2017

Summary

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) pipeline Target constitutes close to 25 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Leukocyte Surface Antigen CD47-Pipeline Review, H2 2017, outlays comprehensive information on the Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)-CD47 (Cluster of Differentiation 47) or integrin associated protein (IAP) is a transmembrane protein encoded by the CD47 gene. It has a role in both cell adhesions by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. It plays an important role in memory formation and synaptic plasticity in the hippocampus (By similarity). It acts as a receptor for SIRPA. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and co-stimulates T-cell activation. It plays an important role in membrane transport and/or integrin dependent signal transduction. It prevents premature elimination of red blood cells. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 11 and 8 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Immunology and Metabolic Disorders which include indications Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Non-Hodgkin Lymphoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Breast Cancer, Diffuse Large B-Cell Lymphoma, Lymphoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Atherosclerosis, Burkitt Lymphoma, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Cutaneous T-Cell Lymphoma, Diabetic Retinopathy, Follicular Lymphoma, Head And Neck Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Ischemia Reperfusion Injury, Kidney Transplant Rejection, Leukemias, Marginal Zone B-cell Lymphoma, Metastatic Breast Cancer, Metastatic Melanoma, Mycosis Fungoides, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma and T-Cell Lymphomas.

Furthermore, this report also reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)

The report reviews Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics and enlists all their major and minor projects

The report assesses Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it'smost promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)-Overview

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)-Companies Involved in Therapeutics Development

Aurigene Discovery Technologies Ltd

Celgene Corp

Forty Seven Inc

GigaGen Inc

Hummingbird Bioscience Pte Ltd

NovImmune SA

PharmAbcine Inc

Surface Oncology Inc

Synthon Holdings BV

Trillium Therapeutics Inc

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)-Drug Profiles

ALX-148-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

B-6H12-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Target CD47 and PDL1 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-90002-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Inhibit CD47 for Non-Small Cell Lung Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HMBD-003-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HMBD-004-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hu-5F9G4-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMM-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMM-02-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMM-03-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMM-2502-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMM-2504-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit CD47 for Metastatic Melanoma-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit CD47 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NI-1701-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NI-1801-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Inhibit CD47 for Immuno-Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PSTx-23-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CD47 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRF-231-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ti-061-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TTI-621-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TTI-622-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)-Dormant Products

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)-Product Development Milestones

Featured News & Press Releases

Dec 11, 2017: Trillium Therapeutics Provides Update on Its TTI-621 Program at the American Society of Hematology 59th Annual Meeting

Dec 06, 2017: Forty Seven Receives $5 Million Grant from The California Institute for Regenerative Medicine (CIRM) to Support Ongoing Clinical Trial in Acute Myeloid Leukemia

Nov 13, 2017: Trillium Therapeutics TTI-621 Program Featured at the Society for Immunotherapy of Cancer 32nd Annual Meeting

Nov 13, 2017: Alexo Therapeutics to Present ALX148 Preclinical Data at the 59th American Society of Hematology Annual Meeting (ASH)

Nov 10, 2017: Alexo Therapeutics Presents Preliminary Results from ALX148 Phase 1 Clinical Trial in Patients with Advanced Solid Tumors and Lymphoma

Oct 05, 2017: Alexo Therapeutics to Present ALX148 Clinical Data at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Jun 07, 2017: Trillium Expands Clinical Trial with TTI-621 to Include Combination with PD-1 Blockade

May 31, 2017: Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2017 ASCO Annual Meeting

Apr 10, 2017: Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma

Apr 05, 2017: The Leukemia & Lymphoma Society Expands its Innovative Therapy Acceleration Program with a Novel Immunotherapy for Lymphoma Patients

Apr 03, 2017: Trillium Therapeutics Presents TTI-621 Preclinical Data at AACR Annual Meeting and Provides Clinical Update

Mar 31, 2017: Aurigene to Present Data on CD47-SIRP? interaction program at the AACR

Mar 15, 2017: Patents Licensed to Synthon Relating to the CD47-SIRPa Pathway Resist Challenges in the U.S. and Europe

Feb 24, 2017: Trillium Therapeutics Provides Additional Details on ASCO-SITC Conference Presentation on TTI-

Feb 15, 2017: Trillium Therapeutics to Present New Data from TTI-621 Phase 1 Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Aurigene Discovery Technologies Ltd, H2 2017

Pipeline by Celgene Corp, H2 2017

Pipeline by Forty Seven Inc, H2 2017

Pipeline by GigaGen Inc, H2 2017

Pipeline by Hummingbird Bioscience Pte Ltd, H2 2017

Pipeline by NovImmune SA, H2 2017

Pipeline by PharmAbcine Inc, H2 2017

Pipeline by Surface Oncology Inc, H2 2017

Pipeline by Synthon Holdings BV, H2 2017

Pipeline by Trillium Therapeutics Inc, H2 2017

Dormant Projects, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Aurigene Discovery Technologies Ltd

Celgene Corp

Forty Seven Inc

GigaGen Inc

Hummingbird Bioscience Pte Ltd

NovImmune SA

PharmAbcine Inc

Surface Oncology Inc

Synthon Holdings BV

Trillium Therapeutics Inc

Company Profile

Company Profile Title

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)-Pipeline Review, H2 2017

Summary

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) pipeline Target constitutes close to 25 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Leukocyte Surface Antigen CD47-Pipeline Review, H2 2017, outlays comprehensive information on the Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)-CD47 (Cluster of Differentiation 47) or integrin associated protein (IAP) is a transmembrane protein encoded by the CD47 gene. It has a role in both cell adhesions by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. It plays an important role in memory formation and synaptic plasticity in the hippocampus (By similarity). It acts as a receptor for SIRPA. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and co-stimulates T-cell activation. It plays an important role in membrane transport and/or integrin dependent signal transduction. It prevents premature elimination of red blood cells. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 11 and 8 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Immunology and Metabolic Disorders which include indications Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Non-Hodgkin Lymphoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Breast Cancer, Diffuse Large B-Cell Lymphoma, Lymphoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Atherosclerosis, Burkitt Lymphoma, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Cutaneous T-Cell Lymphoma, Diabetic Retinopathy, Follicular Lymphoma, Head And Neck Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Ischemia Reperfusion Injury, Kidney Transplant Rejection, Leukemias, Marginal Zone B-cell Lymphoma, Metastatic Breast Cancer, Metastatic Melanoma, Mycosis Fungoides, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma and T-Cell Lymphomas.

Furthermore, this report also reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)

The report reviews Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics and enlists all their major and minor projects

The report assesses Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it'smost promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)-Overview

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)-Companies Involved in Therapeutics Development

Aurigene Discovery Technologies Ltd

Celgene Corp

Forty Seven Inc

GigaGen Inc

Hummingbird Bioscience Pte Ltd

NovImmune SA

PharmAbcine Inc

Surface Oncology Inc

Synthon Holdings BV

Trillium Therapeutics Inc

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)-Drug Profiles

ALX-148-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

B-6H12-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Target CD47 and PDL1 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-90002-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Inhibit CD47 for Non-Small Cell Lung Cancer-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HMBD-003-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HMBD-004-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hu-5F9G4-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMM-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMM-02-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMM-03-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMM-2502-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMM-2504-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit CD47 for Metastatic Melanoma-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit CD47 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NI-1701-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NI-1801-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Inhibit CD47 for Immuno-Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PSTx-23-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CD47 for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRF-231-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ti-061-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TTI-621-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TTI-622-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)-Dormant Products

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)-Product Development Milestones

Featured News & Press Releases

Dec 11, 2017: Trillium Therapeutics Provides Update on Its TTI-621 Program at the American Society of Hematology 59th Annual Meeting

Dec 06, 2017: Forty Seven Receives $5 Million Grant from The California Institute for Regenerative Medicine (CIRM) to Support Ongoing Clinical Trial in Acute Myeloid Leukemia

Nov 13, 2017: Trillium Therapeutics TTI-621 Program Featured at the Society for Immunotherapy of Cancer 32nd Annual Meeting

Nov 13, 2017: Alexo Therapeutics to Present ALX148 Preclinical Data at the 59th American Society of Hematology Annual Meeting (ASH)

Nov 10, 2017: Alexo Therapeutics Presents Preliminary Results from ALX148 Phase 1 Clinical Trial in Patients with Advanced Solid Tumors and Lymphoma

Oct 05, 2017: Alexo Therapeutics to Present ALX148 Clinical Data at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Jun 07, 2017: Trillium Expands Clinical Trial with TTI-621 to Include Combination with PD-1 Blockade

May 31, 2017: Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2017 ASCO Annual Meeting

Apr 10, 2017: Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma

Apr 05, 2017: The Leukemia & Lymphoma Society Expands its Innovative Therapy Acceleration Program with a Novel Immunotherapy for Lymphoma Patients

Apr 03, 2017: Trillium Therapeutics Presents TTI-621 Preclinical Data at AACR Annual Meeting and Provides Clinical Update

Mar 31, 2017: Aurigene to Present Data on CD47-SIRP? interaction program at the AACR

Mar 15, 2017: Patents Licensed to Synthon Relating to the CD47-SIRPa Pathway Resist Challenges in the U.S. and Europe

Feb 24, 2017: Trillium Therapeutics Provides Additional Details on ASCO-SITC Conference Presentation on TTI-

Feb 15, 2017: Trillium Therapeutics to Present New Data from TTI-621 Phase 1 Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Aurigene Discovery Technologies Ltd, H2 2017

Pipeline by Celgene Corp, H2 2017

Pipeline by Forty Seven Inc, H2 2017

Pipeline by GigaGen Inc, H2 2017

Pipeline by Hummingbird Bioscience Pte Ltd, H2 2017

Pipeline by NovImmune SA, H2 2017

Pipeline by PharmAbcine Inc, H2 2017

Pipeline by Surface Oncology Inc, H2 2017

Pipeline by Synthon Holdings BV, H2 2017

Pipeline by Trillium Therapeutics Inc, H2 2017

Dormant Projects, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Aurigene Discovery Technologies Ltd

Celgene Corp

Forty Seven Inc

GigaGen Inc

Hummingbird Bioscience Pte Ltd

NovImmune SA

PharmAbcine Inc

Surface Oncology Inc

Synthon Holdings BV

Trillium Therapeutics Inc